Moderna, Inc.
Clinical trials sponsored by Moderna, Inc., explained in plain language.
Moderna, Inc.
MRNA
NASDAQ
A biotechnology company known for its mRNA-based vaccines and therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial Results expected Sep 2026 (estimated)
- No treatment, just data: new study tracks rare metabolic disease Results expected Sep 2026 (estimated)
- Could this mRNA vaccine stop the virus behind mono and certain cancers? Results expected Oct 2026 (estimated)
- Moderna launches first human test of mRNA vaccine against Epstein-Barr virus Results expected Oct 2026 (estimated)
- New mRNA therapy aims to control blood sugar in rare genetic disease Results expected Nov 2026 (estimated)